Today is: Sunday, September 07, 2008 Neotrope®
Press Release Writing and News Distribution
Affordable Newswire Services and Targeted Distribution
Send2Press® - Press Release Writing, Targeted News Distribution and Media Relations since 1983 press release services from send2press
Newswire Services Press Release Writing Order Send2Press Services
Affordable Newswire Services and Targeted Distribution
BUSINESS WEB WIRE PR NEWSWIRE SERVICES
Press Release Distribution
PR Services
 Search:     
  Translate Page:  
 

U.S. and World News : Medical : Drugs and Pharmaceuticals News

Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma

Tue, 08 Jul 2008, 14:42:48 EDT
Edited by Carly Zander Email this article Print this news article Share Content  Contact This Company


SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit of Rexin-G, the granting of Orphan Drug Status by the FDA validates the unique clinical development strategy of Epeius Biotechnologies: that is, to demonstrate the profound single-agent efficacy of Rexin-G where traditional treatments have historically failed.

EpeiusThe FDA Orphan Drug Act was designed to encourage the development of new products that demonstrate significant promise for the treatment of very serious or life-threatening conditions that are relatively rare, affecting fewer than 200,000 persons in the United States. Orphan Drug Designation provides important economic incentives and powerful market protections that encourage the development of innovative products in the cancer field. U.S. Orphan Drug Designation provides seven years of market exclusivity for Rexin-G, a reduction in fees and taxes, and additional regulatory support for R&D initiatives.

About Rexin-G
Rexin-G(R), the lead product of Epeius Biotechnologies, is the first in a series of tumor-targeted anti-cancer agents designed to seek out and accumulate in metastatic cancers that have spread throughout the body, delivering a lethal payload of genetic medicine to tumor cells and their associated blood supplies without harming normal cells, tissues, or organ systems. Specifically designed to function within the context of the human circulatory system, the demonstration of single agent-efficacy by Rexin-G in Stage IV or metastatic osteosarcoma (ASCO, 2008) is an indication of the remarkable clinical potential of the precision targeting technologies embodied in its design. The Orphan Drug designation by the FDA represents an important milestone in the clinical development of Rexin-G for osteosarcoma.

About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from gene discovery, designer therapeutics, pathotropic (disease-seeking) targeting, vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform biotechnologies for the benefit of cancer patients worldwide.

To learn more about our pipeline of proprietary biotechnologies that are currently available for licensing and clinical development, please visit us at www.epeiusbiotech.com.


  NEWS SOURCE:  Epeius Biotechnologies Corporation
 Send2Press® is the originating wire service for this story.

» Read More Drugs and Pharmaceuticals News
» Other Send2Press Industry News by Category

More Information and Media Contact:
For questions about this story, contact the news source:
» Click Here for Contact Information
THE CONTENT OF THE ABOVE NEWS STORY WAS PROVIDED BY THE NEWS SOURCE WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT SEND2PRESS (THIS WEBSITE).

R E A D E R   R E S O U R C E S
» E-mail This Article    » Printer-Friendly Version
» Choose RSS News Feeds by Topic
 Subscribe in a reader
Add News to Google   Add News to My Yahoo!   Add News to MyMSN   Add to My Wikio

Bookmark and/or share this content with your social network:
del.icio.us:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma  digg:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma  blinklist:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma  furl:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma  blogmarks:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma  reddit:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma  Y!:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
Add to Mixx!

» Permalink for This Article
[ http://www.send2press.com/newswire/2008-07-0708-004.shtml ]


ADDITIONAL NEWS FROM
Epeius Biotechnologies Corporation

» FDA Grants Epeius Biotechnologies' Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas

» Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma

» Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G

» Targeted Gene Delivery Signals Cancer Vaccination in Vivo

» TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

» More Drugs and Pharmaceuticals News  » Top of Page  » Home

J O U R N A L I S T   R E S O U R C E S

Media Copy of Original Press Release:
Plain Text Copy of News Article  PLAIN TEXT FORMAT (UTF-8)      PDF Text Copy of News Article  PDF FORMAT

» Weekly E-Mail News Summary    » RSS Feeds by Topic
» Add Our Headlines to Your Site Automatically (FREE)

Find More News Content About
Epeius Biotechnologies Corporation

 Site Search:     


O T H E R   R E S O U R C E S
Business Tools:
» Send Your News to the Media
» Targeted News Distribution
» Press Release Writing and Editing
Webmaster Tools:
» Add Our Headlines to Your Website

 
T E R M S   O F   U S E
This article is Copr. © 1983-2008 Neotrope / Send2Press. Reproduction of this news article version requires written authorization. You may freely link to this article. Journalists (see the section "Journalist Resources" above) may use orig. news release as the basis for an article. News Websites may republish the "news release" text version linked to above under "Journalist Resources" except must retain "Send2Press Newswire" as the source of this news if used verbatim. Websites which offer/sell PR or newswire services, or web promotion services, or "splogs" may NOT reprint our content in ANY form. Send2Press Newswire is a service mark of, and "Send2Press" is a registered trademark of, Neotrope. Creative Commons - Some Rights Reserved (3.0) - Attribution Required.

DISCLAIMER: the above article is believed accurate but not guaranteed, and is based on business news supplied by the source (Epeius Biotechnologies Corporation). The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.

REFERENCES: .
VIEWED BY MEDIA (and public): 822 times (1 today, 1 this week, 18 this month, 822 this year)

Drugs and Pharmaceuticals
Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G
CYNACON / OCuSOFT(R) Announces OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies
Targeted Gene Delivery Signals Cancer Vaccination in Vivo
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
Eularis to Address Marketing Return at Japanese Pharmaceutical Marketing Excellence Conference
Eularis to Address Making the Right Research Decision for ROI
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy with No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him
Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
Eularis Exposes Hidden Barriers to Patient Adherence with New Pharmaceutical Industry Report
MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London
Losing Weight But Still Have Belly Bulge?
Myo-Med, Tom Brady and STG Media Corp. Team Up to Jump Start Myo-Med's 2008 Advertising Campaign
Recent Studies Suggest Popular 'Diet Pill' Reduces Acne Breakouts
deverus, Inc. Partners with eScreen Inc. to Offer First and Only Instrumented Instant Drug Testing Device to Clients
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G, a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
New Report Examines Pharmaceutical Sales Force Effectiveness
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product
U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas - New Clintelligence(R) Alignment Module Advances Global Management

» View All News Channels
» Press Release Services
» Send2Press Home Page

U.S. and World News
STG Media Corp. Helps Resolve the Health Issues Associated with Tobacco
Card Cafe Promotes Kira Case to Vice President and General Manager
WhiteFlash.com Pushes Youth 'AWEARness' at Teen Choice 2008
Bob Taylor Achieves Accreditation as a Certified Digital Marketing Consultant (CDMC)
Cognitive Technologies Receives Microsoft Federal Partner Award
Top Haunted Attractions Select INTERACTIVE TICKETING for Online Sales
Major Unofficial Upgrade for Microsoft(R) Windows(R) Vista and XP Released by Extensoft
Arclinea San Diego Wins Two National Design Awards
Home Shopping Latino, Inc. Launches a $6 Million Dollar Global Media Fund Campaign
iSkin's New solo for iPhone 3G Delivers Slim-fitting Protection for a High-Gloss Fashion Makeover
Kathleen Gilmartin Joins Interim HealthCare Inc. as New President and CEO
Georgia Department of Education Launches HOSA Foundation to Promote Careers in Healthcare
Van Millwork Presents Fall 2008 Home Design Series - Informative Seminars for New England Homeowners
Allegro Gets Traction with Direct Marketing Blog
Napco Asset Management and Packman Financial Finalize Merger
Blues Band Aunt Kizzy'z Boyz Beats Out Youthful Competition to Win LAMN Jam Finale by a Landslide
LTC Financial Partners (LTCFP) is Fastest-Growing Long Term Care Insurance Specialist on Inc. Magazine List
LocaModa Interactive Social Media Platform Used to Inspire Public Policy Debates at Both DNC and RNC
Southwest Ohio's First and Largest Outpatient Pain Clinic Continues to Grow Despite Weak Economy
Worldwide Mobile Content Tools Market to Top $8 Billion in 2008, says INSIGHT Research Corp.
Savannah Economic Development Authority brings Savannah to Atlanta Sept. 2
exxHelp Help Doc Builder Software Released
AP Financial, Inc. Opens Another Office in San Diego, California
Libera Acquires Pintexx
Country Swing Makes a Comeback on New Song from Joss and Colosio

» View All News Channels
» Press Release Services
» Send2Press Home Page
Full Text RSS 2.0 news feed RSS 0.91 Summary News Feed Entertainment Podcast RSS Feed
» View Menu of News Feeds by Topic
— ADVERTISEMENT —
Promote Your Company to the Media
and on This Website

Press release services from Neotrope®. Member BBB. Expert PR staff. Targeted solutions since 1983. Learn More
Business News 
 
 U.S. and World News
 Advertising and Marketing
 Aerospace and Aviation
 Agriculture and Farming
 Auction and Online Auctions
 Auto and Motorsports
 Banking and Finance
 Beauty Products
 Boating, Marine and Maritime
 Business
 Communication Arts
 Computing
 Construction and Building
 Corporate Social Responsibility - CSR
 Defense and Military
 Education and Schools
 Electronics
 Employment, HR and Outsourcing
 Energy, Oil and Gas
 Entertainment
 Environment and Ecology
 Facilities and Building Maintenance
 Family, Parenting and Children
 Firearms and Airguns
 Food and Beverages
 General Editorial
 Global Aid and Relief
 Government
 Green Business
 Health, Diet and Fitness
 Home and Garden
 HVAC Heating and Cooling
 Insurance
 Internet and Websites
 Jewelry and Diamond
 Legal and Law
 Manufacturing
 Medical
 Alternative Medicine 
 Biotechnology 
 Cosmetic Surgery 
 Dentistry 
 Devices and Research 
 Disabilities and 508 Compliance 
 Drug Rehabilitation 
 Drugs and Pharmaceuticals 
 Fertility and IVF 
 Hospitals and Nursing 
 Long Term Care 
 Medical and Health Products 
 Medical Business Services 
 Private Practice and Medical Groups 
 Surgery and Neurotechnology 
 Mining and Metals
 NonProfit and Charities
 Plastics and Composites
 Police, Fire and Rescue
 Real Estate
 Regional Events
 Religion and Churches
 Restaurant, Hotel and Hospitality
 Safety and Security Solutions
 Sciences
 Sports and Activities
 Stamps, Coins and Collectables
 Taxes and Accounting
 Telecommunications and VoIP
 Theme Parks and Attractions
 Trade Shows, Fairs and Expos
 Transportation
 Travel and Tourism
 U.S. Companies
 US and World History
 Veterinary and Pets
 
 U.S. State Newswires
 Alabama Business
 Alaska Business
 Arizona Business
 California Business
 Colorado Business
 Connecticut Business
 Florida Business
 Georgia Business
 Hawaii Business
 Idaho Business
 Illinois Business
 Iowa Business
 Kansas Business
 Maryland Business
 Massachusetts Business
 Michigan Business
 Minnesota Business
 Mississippi Business
 Missouri Business
 Nebraska Business
 Nevada Business
 New Jersey Business
 New Mexico Business
 New York Business
 North Carolina Business
 Ohio Business
 Oklahoma Business
 Oregon Business
 Pennsylvania Business
 Puerto Rico Business
 South Carolina Business
 South Dakota Business
 Tennessee Business
 Texas Business
 Utah Business
 Vermont Business
 Virginia Business
 Washington D.C. Business
 Washington State Business
 West Virginia Business
 Wisconsin Business
 
 Video News Releases
 
 World Newswires
 Brazil Business
 Canada Business
 Germany Business
 Spain Business
 United Kingdom

Subscribe to FREE
Send2Press®
Weekly News Alert

» Privacy Statement
» How to Unsubscribe

Click to Hear Podcasts
» Click to Hear Podcasts

Recent Send2Press News Network Placements on:
newswire placement on Google News
Advertising Industry
FURL LookSmart Publishers Newswire
Yahoo! News
Technorati News

INTERNET NEWSWIRE ARCHIVE SPONSORS
Website Promotion Services and SEO PR
Powered by Neotrope®
» View a list of our news archive sponsors
Learn about Send2Press Media Solutions